山东步长制药股份有限公司关于控股子公司山东丹红拟与山东中医药大学附属医院签署《技术转让（开发）合同》的进展公告

Group 1 - The company has signed a technology transfer contract with Shandong University of Traditional Chinese Medicine Affiliated Hospital for the development of a new traditional Chinese medicine product [2][3] - The total technology transfer fee is set at 15 million yuan, which will be paid in installments as per the contract [6] - The contract includes provisions for intellectual property rights, ensuring that the technology and any resulting innovations will belong to the company, while the hospital retains certain academic rights [7][8] Group 2 - The technology being transferred involves the "Er Zhi Tiao Jing Optimization Formula," aimed at developing a new drug for treating conditions related to kidney deficiency [2][3] - The company is responsible for conducting all necessary research and regulatory submissions to achieve national drug registration for the new product [5] - The contract stipulates confidentiality obligations that extend for 20 years post-termination, ensuring that sensitive information remains protected [11][12] Group 3 - The contract outlines specific conditions under which either party can terminate the agreement, including failure to meet research milestones or submission deadlines [13][14] - Dispute resolution will be handled through negotiation, and if unresolved, will be taken to the competent court [17] - The contract is valid for 20 years and requires mutual consent for any amendments [20]